Lonza readies as pharma sector boosts Singapore production

A pharma production boost offset slumping electronics manufacturing, giving Singapore its biggest industrial production surge in 5 months. Pharmaceutical output soared 157%, while electronics production declined 22% compared with a year earlier.

For Singapore, it translates into a 22% industrial production increase over a year ago, according to its Economic Development Board, as reported by Bloomberg.

Manufacturing accounts for more than 20% of Singapore's economy, the report says. The question for economists is whether the August performance is a fluke, the start of a trend, or something else.

Contract manufacturer Lonza, for one, appears to see plenty of potential there. In the last few months, the CMO has announced a $12 million plan to expand its biopharmaceutical development services platform in Singapore and plans a secondary listing on the Singapore Stock Exchange.

- here's the story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)